American Century Companies Inc. Raises Stock Position in AngioDynamics, Inc. (NASDAQ:ANGO)

American Century Companies Inc. increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 22.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,942 shares of the medical instruments supplier’s stock after acquiring an additional 12,306 shares during the period. American Century Companies Inc. owned approximately 0.17% of AngioDynamics worth $622,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Intech Investment Management LLC purchased a new position in shares of AngioDynamics during the fourth quarter worth approximately $152,000. Royce & Associates LP boosted its holdings in AngioDynamics by 13.5% during the fourth quarter. Royce & Associates LP now owns 1,119,385 shares of the medical instruments supplier’s stock worth $10,254,000 after buying an additional 133,312 shares in the last quarter. First Eagle Investment Management LLC boosted its position in AngioDynamics by 4.1% during the fourth quarter. First Eagle Investment Management LLC now owns 410,335 shares of the medical instruments supplier’s stock worth $3,759,000 after purchasing an additional 16,221 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. grew its stake in AngioDynamics by 69.0% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 389,053 shares of the medical instruments supplier’s stock valued at $3,564,000 after acquiring an additional 158,897 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in shares of AngioDynamics by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 329,090 shares of the medical instruments supplier’s stock valued at $3,014,000 after purchasing an additional 2,270 shares during the last quarter. Institutional investors and hedge funds own 89.43% of the company’s stock.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total value of $49,978.60. Following the transaction, the senior vice president now owns 41,817 shares in the company, valued at approximately $514,767.27. This represents a 8.85 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 5.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price objective (up previously from $15.00) on shares of AngioDynamics in a research report on Monday.

AngioDynamics Stock Performance

ANGO opened at $9.29 on Friday. The company has a market capitalization of $377.24 million, a P/E ratio of -1.65 and a beta of 0.52. AngioDynamics, Inc. has a 1-year low of $5.47 and a 1-year high of $13.50. The company has a 50-day moving average of $9.80 and a 200-day moving average of $8.95.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16. The business had revenue of $72.00 million during the quarter, compared to analyst estimates of $70.30 million. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business’s quarterly revenue was down 4.3% compared to the same quarter last year. As a group, sell-side analysts expect that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.